Ribavirin
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide <ref>DOI: 10.1093/jac/dki405 </ref> | + | 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide <ref name="gish">DOI: 10.1093/jac/dki405 </ref> |
| - | <StructureSection load='' size='340' side='right' caption=' | + | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='74/746008/Ribavirin_atalla/1'> |
| - | <scene name='74/746008/ | + | <scene name='74/746008/Ribavirin_atalla/1'>TextToBeDisplayed</scene> |
| - | + | ||
| - | + | ||
== Overview == | == Overview == | ||
| - | Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C. The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b <ref>DOI: 10.1093/jac/dki405 </ref>. | + | Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C. The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b <ref name="gish"/>DOI: 10.1093/jac/dki405 </ref>. |
| - | + | ||
== Structure & Function == | == Structure & Function == | ||
| Line 14: | Line 11: | ||
== Disease == | == Disease == | ||
===Hepatitis C=== | ===Hepatitis C=== | ||
| - | Hepatitis C is an infectious disease that affects the liver due to the Hepatitis C virus (HCV). This disease can be acute or chronic and can even lead to death. By binding to the gC1qR receptor, HCV proteins are able to effectively inhibit the differentiation of helper T cells. In addition, HCV core proteins work by preventing the synthesis of the antiviral interferon IFN-γ. Thus, weakening the body’s immunity and making it susceptible to infection. Ribavirin is used in combination with peginterferon to treat Hepatitis C.<ref>doi: 10.1002/hep.22070</ref> By adding pegylated interferon-alpha to ribavirin, the drug had a longer half life, which required only single weekly dosing for Hepatitis C treatment. <ref>doi: 10.1016/j.coviro.2011.10.030</ref> | + | Hepatitis C is an infectious disease that affects the liver due to the Hepatitis C virus (HCV). This disease can be acute or chronic and can even lead to death. By binding to the gC1qR receptor, HCV proteins are able to effectively inhibit the differentiation of helper T cells. In addition, HCV core proteins work by preventing the synthesis of the antiviral interferon IFN-γ. Thus, weakening the body’s immunity and making it susceptible to infection. Ribavirin is used in combination with peginterferon to treat Hepatitis C.<ref>doi: 10.1002/hep.22070</ref> By adding pegylated interferon-alpha to ribavirin, the drug had a longer half life, which required only single weekly dosing for Hepatitis C treatment. <ref>doi: 10.1016/j.coviro.2011.10.030</ref> Polyethylene glycol (PEG) is covalently attached with two types:1. P-INFa-2b and 2. P-INFa-2a. While P-INFa-2b is linear and subject to hydrolysis upon injection, P-INFa-2a is branched and circulated the molecule as a whole. The limited distribution of P-INFa-2a results in a longer half life. <ref>doi:10.2165/11531990-000000000-00000</ref> |
| - | + | ||
===Pneumonia=== | ===Pneumonia=== | ||
Respiratory syncytial virus is responsible for viral pneumonia. This infection causes the air sacs in one or both of the lungs to become inflamed and potentially filled with fluid or pus. In infants, children, and adults over the age of 65, pneumonia can be deadly. It has been shown that Ribavirin can treat viral pneumonia by preventing transcription of respiratory syncytial virus. <ref> National Heart, Lung and Blood Institute. (2016, September 26). Pneumonia. Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu </ref> | Respiratory syncytial virus is responsible for viral pneumonia. This infection causes the air sacs in one or both of the lungs to become inflamed and potentially filled with fluid or pus. In infants, children, and adults over the age of 65, pneumonia can be deadly. It has been shown that Ribavirin can treat viral pneumonia by preventing transcription of respiratory syncytial virus. <ref> National Heart, Lung and Blood Institute. (2016, September 26). Pneumonia. Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu </ref> | ||
| Line 22: | Line 18: | ||
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | ||
| - | [[Image:Mechanisms.png | thumb]] | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
| - | + | # Gish, R. G. (2005, November 17). Treating HCV with ribavirin analogue and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy, 1-6. doi:10.1093/jac/dki405 | |
| - | + | # Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. (2008). Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology, 47 (1), 306-320. doi: 10.1002/hep.22070 | |
| - | + | # Paeshuyse, J, Dallmeier, K, Neyts, J. (2011). Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology. 1(6): 590-598. doi: 10.1016/j.coviro.2011.10.030 | |
| - | + | # National Heart, Lung and Blood Institute. (2016, September 26). Pneumonia. Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu | |
| + | # Foster, G. (2010). Pegylated interferons for the treatment of chronic Hepatitis C. Drugs. 70(2):147-165. doi:10.2165/11531990-000000000-00000 | ||
Revision as of 03:06, 16 November 2016
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide [1]
| |||||||||||
References
- Gish, R. G. (2005, November 17). Treating HCV with ribavirin analogue and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy, 1-6. doi:10.1093/jac/dki405
- Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. (2008). Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology, 47 (1), 306-320. doi: 10.1002/hep.22070
- Paeshuyse, J, Dallmeier, K, Neyts, J. (2011). Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology. 1(6): 590-598. doi: 10.1016/j.coviro.2011.10.030
- National Heart, Lung and Blood Institute. (2016, September 26). Pneumonia. Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu
- Foster, G. (2010). Pegylated interferons for the treatment of chronic Hepatitis C. Drugs. 70(2):147-165. doi:10.2165/11531990-000000000-00000
Proteopedia Page Contributors and Editors (what is this?)
Jamie Costa, Edmond R Atalla, Katherine Reynolds, Taylor H. Derby, Shannon Shaughnessy, Alexander Berchansky
